Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate the Efficacy and Safety of Topical Ocular MG-O-1002 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05390840 is registered in ClinicalTrials.gov with Theratocular Biotek Co. as lead sponsor.

NCT NCT05390840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05390840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate the Efficacy and Safety of Topical Ocular MG-O-1002 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Lead sponsor
Theratocular Biotek Co.
Phase
Phase 2
Overall status
Unknown status
Start date
August 9, 2022
Completion date
March 31, 2024
Enrollment
36 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration